[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"healthy-adult\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:healthy-adult":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,46,0,25,[9,43,77,97,122,147,176,211,229,254,278,298,326,352,384,421,444,474,495,518,542,562,594,620,651],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100635304","phase-1-study-to-evaluate-the-effect-of-food-and-a-proton-pump-inhibitor-on-the-pharmacokinetics-of-vrn101099-in-healthy-adult-participants-100635304",false,"NCT07550946","Study to Evaluate the Effect of Food and a Proton Pump Inhibitor on the Pharmacokinetics of VRN101099 in Healthy Adult Participants","A Phase 1, Open-label, Randomized, 3-Period, 2-Sequence, Crossover Study to Evaluate the Effect of Food and a Proton Pump Inhibitor on the Pharmacokinetics of VRN101099 in Healthy Adult Participants","Inclusion Criteria:\n\n1. Male or female aged between 18 and 65 years of age (inclusive at the time of informed consent).\n2. In good general health, with no significant medical history, and have no clinically significant abnormalities on physical examination at Screening and\u002For before the first administration of IP (at the discretion of the PI or designee).\n3. BMI between ≥ 18.0 and ≤ 32.0 kg\u002Fm2 and weight ≥ 50 kg at Screening.\n4. Clinical laboratory values within normal range as specified by the testing laboratory, unless deemed not clinically significant by the PI or designee. Note: Repeat testing at Screening is acceptable for out-of-range values at the discretion of the Investigator.\n5. Female participants must be either not of childbearing potential or if they are a woman of childbearing potential and are engaged in heterosexual intercourse, they must agree to use an acceptable, highly effective contraception method in conjunction with a condom for the male partner from Screening until 100 days after the last dose of IP (ie, 90 days plus 5 half-lives of the IP).\n6. Male participants must not be of childbearing potential, or if they are engaged in sexual relations with WOCBP, they must agree to use a condom in conjunction with an acceptable, highly effective contraception method for the female partner from Screening until 100 days after the last dose of the IP.\n7. Males must not donate sperm and females must not donate ova from the first dose of IP until at least 100 days after the last dose of IP (ie, 90 days plus 5 half-lives of the IP).\n8. Able and willing to attend the necessary visits to the CRU.\n9. Able and willing to provide written informed consent after the nature of the study has been explained and prior to the commencement of any study procedures.\n\nExclusion Criteria:\n\n1. Underlying physical or psychological medical condition that, in the opinion of the PI or designee, would make it unlikely for the participant to comply with the protocol or complete the study per protocol. This includes but may not be limited to: medical histories (eg, hepatic\u002Fbiliary, renal, cardiovascular, endocrine, respiratory, digestive, haematologic, oncologic \\[except for non-melanoma skin cancer, excised more than 2 years ago and cervical intraepithelial neoplasia that has been successfully cured more than 5 years prior to the first administration of IP\\], central nervous system, psychiatric, musculoskeletal) or past medical\u002Fsurgical histories that may affect drug absorption, distribution, metabolism, or excretion (excluding simple appendectomy or herniorrhaphy).\n2. Participants with known or suspected conditions or significant gastrointestinal disorders that may interfere with drug absorption (eg, inflammatory bowel disease, chronic diarhoea, malabsorption syndromes, or prior gastrointestinal surgery affecting absorption).\n3. History of severe allergic or anaphylactic reactions, or sensitivity to the IP or its constituents.\n4. History of hypersensitivity and\u002For intolerance to PPIs.\n5. History of infections requiring parenteral antibiotics within 6 months prior to the first administration of IP.\n6. Blood donations of ≥ 400 mL or significant blood loss within 60 days prior to the first administration of investigational product (IP), plasma donation within 7 days prior to the first administration of IP, or platelet donation within 30 days prior to the first administration of IP. Participants must also agree not to donate blood, plasma, or platelets during the study and for at least 30 days after the last dose of IP.\n7. Abnormal findings on 12-lead (triplicate) ECG at Screening that are considered by the PI or designee to be clinically significant; or has a QTcF (Fridericia's formula) interval at Screening of \\> 450 msec for males or \\> 470 msec for females based on the average of the 3 readings. Repeat testing at Screening is acceptable for abnormal values at the discretion of the Investigator (once per parameter).\n8. Abnormal vital sign findings at Screening that are considered clinically significant by the Principal Investigator (PI) or designee, including systolic blood pressure \\>140 mmHg or \\\u003C 90 mmHg, diastolic blood pressure \\> 90 mmHg or \\\u003C 50 mmHg, or a history of symptomatic hypotension. If a screening value falls outside these limits, repeat measurement is permitted at the discretion of the Investigator, with one repeat assessment allowed per parameter. Eligibility should be based on the repeat value.\n9. Active liver disease, or AST and\u002For ALT \\> 1.5 × upper limit of normal at Screening. Note: Repeat testing at Screening is acceptable for out-of-range values at the discretion of the Investigator.\n10. Estimated glomerular filtration rate (eGFR) of ≤ 80 mL\u002Fmin\u002F 1.73 m2 based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) 2021 formula.\n11. Positive test for hepatitis C antibody (HCV), hepatitis B surface antigen (HBsAg), or human immunodeficiency virus (HIV) antibody at Screening.\n12. Use of (or anticipated use of) any prescription drugs (other than hormonal contraception; oral contraceptive pills, long-acting implantable hormones, injectable hormones, a vaginal ring, or an intrauterine device), within 14 days prior to the first administration of the IP; or use of any over the counter medication, herbal remedies, supplements, or vitamins within 7 days prior to the first administration of IP and during course of study. Note: Simple analgesia (eg, paracetamol) may be permitted at the discretion of the PI, provided they are used within the recommended maximum daily doses as specified in the package insert.\n13. Use of any drugs, herbal supplements, or foods that are known to be strong or moderate inhibitors\u002Finducers of CYP3A4 (eg, carbamazepine, rifampin, St. John's wort, ketoconazole, ginkgo biloba, grapefruit, grapefruit juice) from within 30 days prior to the first administration of IP until the end of the study.\n14. Use of PPIs, histamine (H)2 blockers, potassium-competitive acid blockers, or locally-acting antacids within 8 weeks before the first dose of IP, or requiring these medications during the study (except for the planned use of rabeprazole specified in the protocol)\n15. Vaccination with a live vaccine within 4 weeks prior to the first administration of IP (and up until 14 days after the last dose of the IP).\n16. Use of any IP or investigational medical device within 30 days prior to the first administration of IP, or 5 half lives of the product (whichever is the longest), and during the course of the study.\n17. Positive toxicology screening panel (urine test including qualitative identification of amphetamines, methamphetamines, methadone, barbiturates, benzodiazepines, cocaine, opiates, methylenedioxymethamphetamine, phencyclidine, tetrahydrocannabinol, and tricyclic antidepressants), or alcohol breath test at Screening. Note: A single repeat test in the event of a false positive is permitted for the drug of abuse urine test at the discretion of the Investigator.\n18. History of regular alcohol consumption defined as \\> 14 standard drinks per week or \\> 3 standard drinks on any single day (where 1 standard drink = 10 g of alcohol) within 3 months prior to Screening.\n19. Unwilling or unable to abstain from the consumption of alcohol and caffeine containing food or drinks beginning 72 hours prior to the first administration of IP and until the end of the study.\n20. Unwilling to abstain from cigarettes or nicotine-containing products (eg, cigars, vapes, nicotine patches) for at least 7 days prior to first IP administration through to the end of the study, or is considered to be dependent on nicotine at the discretion of the PI. Note: Participants that are considered light or social smokers (defined as ≤ 5 cigarettes per week) will be considered eligible for entry into the study but must also adhere to these restrictions.\n21. Unwilling to refrain from strenuous exercise (including weightlifting) from 48 hours prior to each admission (on Day -1, Day 11, and Day 28), during the inpatient stays, and for 48 hours prior to any outpatient visit (including the EOS visit).\n22. Unable or unwilling to consume a high-fat meal.\n23. Pregnant or lactating.\n24. Poor peripheral venous access.\n25. Anything that the PI considers that would jeopardize the safety of the participant, prevent complete participation in the study, or compromise interpretation of study data.",true,"ALL","18 Years","65 Years",{"count":22,"type":23},24,"ESTIMATED","INTERVENTIONAL",[26],"PHASE1","This Clinical trial is being done to understand how food and a common stomach-acid reducing medicine (called a proton pump inhibitor-PPI) affect how the body absorbs a new drug, VRN101099, in healthy adults.\n\nResearchers will measure how much of the drug gets into the bloodstream and how fast it gets there in each situation.\n\nThis will help identify the most effective way for future patients to use VRN101099 in the treatment of solid tumors and cancers.\n\nThe main questions it aims to answer is:\n\n1. Does food or a PPI change how the body absorbs a single dose of VRN101099?\n2. Is a single dose of VRN101099 safe and well tolerated when taken with or without food or a PPI?\n3. How is VRN101099 removed through urine when taken with or without food or a PPI?",[29],"Healthy Adult","RECRUITING","2026-08-19",{"date":33,"type":34},"2026-08-21","ACTUAL",{"date":36,"type":34},"2026-06-22",{"date":38,"type":23},"2026-09-30",{"name":40,"class":41},"Voronoi, Inc","INDUSTRY",1,{"id":44,"slug":45,"hasResults":12,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":24,"phases":52,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":42},"100623141","aldh2-genetic-testing-in-east-asian-community-100623141","NCT07392775","ALDH2 Genetic Testing in East Asian Community","A Community-Based Approach for ALDH2 Genetic Testing in East Asian Americans","Inclusion Criteria:\n\n1. Age 18 or older\n2. Self-identified as East Asian and\u002For East Asian American\n3. Flush when they drink alcohol or have a family member who flushes when they drink\n4. Able to read and speak English",{"count":51,"type":23},100,[53],"NA","The goal of this clinical trial is to learn whether education plus genetic testing for ALDH2\\*2 and ADH1B\\*2 is feasible and acceptable and whether it influences modifiable health behaviors in East Asian American adults who experience alcohol flushing when they drink alcohol or have a family history of flushing. The main questions it aims to answer are:\n\n1. Is providing education plus ALDH2\\*2\u002FADH1B\\*2 genetic testing feasible and acceptable in a clinical care context?\n2. Does receiving genetic testing results plus education lead to changes in modifiable health behaviors compared with education alone? Researchers will compare education plus genetic testing (intervention arm) to education only (control arm) to see if adding genetic testing improves feasibility\u002Facceptability and supports health behavior change.\n\nParticipants will:\n\n1. Complete an education module about alcohol flushing and ALDH2\u002FADH1B\n2. Be randomized to either: (A) Receive genetic testing for ALDH2\\*2 and ADH1B\\*2 with results disclosure, or (B) Receive education only.\n3. Complete follow-up measures about feasibility, acceptability, and modifiable health behaviors",[29,56],"Flushing",[58,59,60,61,62,63,64,65],"East Asian","Alcohol Flushing","ALDH2","ADH1B","Esophageal Cancer","Genetic Testing","Alzheimer's Disease","Cardiovascular Disease","NOT_YET_RECRUITING","2026-08-07",{"date":69,"type":34},"2026-08-11",{"date":71,"type":23},"2026-11-01",{"date":73,"type":23},"2029-06-30",{"name":75,"class":76},"Northwestern University","OTHER",{"id":78,"slug":79,"hasResults":12,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":84,"targetDuration":4,"studyType":24,"phases":86,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":42},"100651191","phase-1-bridging-study-of-xkh001-in-healthy-adult-caucasian-participants-100651191","NCT07757659","Bridging Study of XKH001 in Healthy Adult Caucasian Participants","A Phase Id, Randomised, Double-Blind, Placebo-Controlled, Multiple-Dose Bridging Study To Evaluate The Pharmacokinetics, Safety, Tolerability, and Immunogenicity of XKH001 in Healthy Adult Caucasian Participants","Inclusion Criteria:\n\n1. Healthy participants who voluntarily provide written informed consent and can comply with all study procedures according to the protocol.\n2. Male or female participants of Caucasian ethnicity(both biological parents and all four grandparents of Caucasian origin), 18-65 years of age (inclusive).\n3. Body mass index (BMI) between 18.0-32.0 kg\u002Fm² (inclusive).\n4. Vital signs, physical examination, clinical laboratory tests, and 12-lead electrocardiogram (ECG) within normal limits or considered not clinically significant by the investigator, with QTcF ≤450 ms.\n5. No use of prescription or over-the-counter medications within 4 weeks prior to first dosing.\n6. Participants must meet the sex- and reproductive-status-specific contraception and gamete-donation requirements specified in Appendix 2. Where contraception is required, the participant must agree to use the protocol-specified established effective contraception from the time of signing the informed consent form until 7 months after the last dose of study drug.\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding women.\n2. Any clinically significant disease within 5 years that could affect participation (gastrointestinal, renal, hepatic, pulmonary, neurology, Haematology, endocrine, oncology, metabolic, psychiatric, or cerebrovascular).\n3. History of autoimmune disease, known hereditary immunodeficiency, or recurrent infections suggesting immunodeficiency.\n4. Active infection requiring hospitalisation or IV antibiotics within 3 months, or clinically symptomatic bacterial, viral, or fungal infection within 4 weeks prior to first dosing.\n5. Active or latent tuberculosis infection.\n6. HBsAg positive, HCV antibody positive, syphilis antibody positive, or HIV antigen\u002Fantibody positive.\n7. Live or attenuated vaccine within 4 weeks prior to dosing or planned during trial.\n8. Participation in any clinical trial within 3 months or 5 half-lives of the investigational drug (whichever is longer) prior to dosing.\n9. History of allergy to the investigational drug, any formulation component, or protein-based drugs.\n10. Alcohol consumption \\>14 units\u002Fweek within 6 weeks prior to screening, or alcohol-containing products within 1 day before dosing (1 unit = 8 g or 10 mL of pure alcohol).\n11. Drug abuse or illicit substance use within 5 years, or positive urine drug screen(A positive cotinine result alone is not exclusionary).\n12. Smoking history (\\>5 cigarettes\u002Fday) within 3 months prior to screening.\n13. Blood donation or loss \\>450 mL within 8 weeks, or \\>200 mL blood donation or \\>300 mL blood loss within 1 month.\n14. Unsuitable venous access or intolerance of venipuncture.\n15. Prior exposure to any anti-IL-25 therapeutic agent, including XKH001 or any other investigational or approved therapeutic agent targeting IL-25.\n16. Any other reason deemed unsuitable by the investigator.",{"count":85,"type":23},2,[26],"This is a Phase Id, randomised, double-blind, placebo-controlled, multiple-dose, bridging study conducted at a single Phase I clinical research unit in Australia. The study is designed to evaluate the pharmacokinetics, safety, tolerability, and immunogenicity of XKH001 following repeated subcutaneous administration in healthy adult Caucasian participants, and to provide an ethnic-bridging pharmacokinetic comparison with the prior Phase I dataset in Chinese participants, required for XKH001's global development programme.",[29],"2026-08-05",{"date":69,"type":34},{"date":92,"type":23},"2026-08-01",{"date":94,"type":23},"2027-08-01",{"name":96,"class":41},"Zhejiang Kanova Biopharmaceutical Co., LTD",{"id":98,"slug":99,"hasResults":12,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":103,"eligibilityCriteria":104,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":105,"enrollmentInfo":106,"targetDuration":4,"studyType":24,"phases":108,"briefSummary":109,"conditions":110,"keywords":111,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":118,"leadSponsor":120,"locationsCount":42},"100632763","cerebrospinal-fluid-kinetics-of-urolithin-a-100632763","NCT07517913","Cerebrospinal Fluid Kinetics of Urolithin A","Cerebrospinal Fluid Kinetics of Urolithin A in Humans","neURO","Inclusion Criteria:\n\n* 1\\. Healthy male and female participants aged between 18 and 45 years (both inclusive);\n* 2\\. Non-smoker subject or smoker of not more than 5 cigarettes a day;\n* 3\\. Body Mass Index (BMI) between 18.50-30.00 kg\u002Fm2 inclusive;\n* 4\\. Trial participants in normal health as determined by personal medical history, clinical examination including vital signs, and clinically acceptable results of laboratory examinations (including serological tests), individual values out of the normal range can be accepted if judged clinically non relevant by the Investigator;\n* 5\\. Normal electrocardiogram (ECG) recording on a 12-lead ECG and\u002For chest X-ray (PA view) significant at the screening visit or considered not clinically significant (NCS) by investigators;\n* 6\\. A negative alcohol breath test result at housing;\n* 7\\. Trial participant able to communicate effectively, provide voluntary written informed consent and available for the entire study duration;\n* 8\\. Trial participants willing to adhere to the protocol requirements as evidenced by written informed consent approved by the ethics committee;\n* 9\\. Ability to fast for at least 14.00 hours and consume standard meals;\n* 10\\. Accept to refrain consuming certain foods and supplements at least two weeks before inclusion;\n* 11\\. Female participants must have a negative urine pregnancy test prior to housing;\n* 12\\. Trial participants that can provide adequate evidence of their identity;\n* 13\\. The participants agree to refrain from consuming dietary supplements that could potentially impact either muscle or mitochondrial function or contain Urolithin A, such as resveratrol, pomegranate and ellagitannins, nicotinamide riboside, whey protein, leucine, iso-leucine, l-carnitine, creatinine, coenzyme Q10, vitamin A, niacin, folic acids, vitamin C, vitamin E and probiotic foods and supplements, during the 2 weeks before inclusion and throughout the study;\n* 14\\. Females of childbearing potential agree to use appropriate contraceptive measures like non-hormonal intrauterine devices, barrier methods, and spermicidal agents during the study and 07 days after completion of the study;\n* 15\\. Male agreeing to use appropriate contraceptive measures like the Double Barrier method (Condom), and should not donate sperm, etc. during the study and 07 days after completion of the study.\n\nExclusion Criteria:\n\n* 1\\. Known hypersensitivity to Urolithin A or related product or any component of intervention, presence or history of drug hypersensitivity, allergic disease or lactose intolerance;\n* 2\\. Any history or presence of clinically significant medical condition, such as, but not limited to, cardiovascular, pulmonary, gastro-intestinal, hepatic, renal, metabolic, hematological, neurologic, psychiatric, systemic or infectious disease, thyroid disease, adrenal dysfunction, or organic intracranial lesion;\n* 3\\. Any treatment which could bring about induction or inhibition of the hepatic microsomal enzyme system within one month of starting the study;\n* 4\\. History or presence of alcoholism or drug abuse;\n* 5\\. History or presence of gastric and\u002For duodenal ulceration;\n* 6\\. History or presence of cancer;\n* 7\\. Difficulty with donating blood;\n* 8\\. Use of any prescribed medication (including herbal remedies) during the two weeks before the start of the study or OTC medicinal products (including herbal remedies) during the week before study initiation and throughout the study;\n* 9\\. Use of medications such as benzodiazepines, anticonvulsants, or barbiturates for one month before the start of the study and throughout the study;\n* 10\\. Trial participant consumed tobacco\u002Ftobacco-containing products, pan or pan masala, gutkha, and masala (containing beetle nut and tobacco) for at least 48.00 hours before initiation of the study and throughout the study;\n* 11\\. Trial participant consumed caffeine and\u002For xanthine-containing foods or beverages (i.e., coffee, tea, chocolate, and caffeine-containing sodas, colas, etc.) and grapefruit juice and poppy-containing foods for at least 48.00 hours before initiation of the study and throughout the study;\n* 12\\. Major illness during the 90 days before screening;\n* 13\\. Participation in a drug research study within 90 days of screening;\n* 14\\. Positive screening test result for any one or more of the following: HIV, Hepatitis B, Hepatitis C, and VDRL;\n* 15\\. History or presence of easy bruising or bleeding;\n* 16\\. Abnormal diet pattern for whatever reason (e.g., low sodium, fasting, and high protein diets) during the four weeks preceding the study;\n* 17\\. Females of childbearing potential with any one of the following reported and documented on the medical history:i. Postmenopausal with spontaneous amenorrhea for at least one year, orii. Bilateral oophorectomy with or without a hysterectomy and an absence of bleeding for at least 6 months, oriii. Total hysterectomy and an absence of bleeding for at least 3 months;iv. Female volunteers who have used implanted or injected hormonal contraceptives anytime during the 6 months prior to study or used hormonal contraceptives within 07 days before dosing;\n* 18\\. Pregnant women and nursing mothers;\n* 19\\. Male and females of childbearing potential unwilling to employ appropriate and reliable method of contraception like non-hormonal intrauterine devices, barrier methods, and spermicidal agents, Double Barrier method (Condom) during the study till 07 days after the completion of the study;\n* 20\\. Male volunteers willing to donate sperm during the study till 07 days after the completion of the study.\n* 21\\. Allergy to peanuts, nuts, pea, or gum guar.","45 Years",{"count":107,"type":23},40,[53],"The purpose of this study is to determine the impact of Mitopure® consumption on urolithin A (UA) kinetics in cerebral spinal fluid (CSF).",[29],[112,113],"Mitopure","Urolithin A","2026-07-28",{"date":116,"type":34},"2026-07-29",{"date":92,"type":23},{"date":119,"type":23},"2027-06-01",{"name":121,"class":41},"Amazentis SA",{"id":123,"slug":124,"hasResults":12,"nctId":125,"briefTitle":126,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":128,"targetDuration":4,"studyType":24,"phases":130,"briefSummary":131,"conditions":132,"keywords":133,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":42},"100648726","testing-of-personal-protective-equipment-ppe-for-first-responders-100648726","NCT07726537","Testing of Personal Protective Equipment (PPE) for First Responders","Inclusion Criteria:\n\nThe study will be open to employees or students of:\n\n* the KAGES hospital, Graz, Austria\n* the Medical University of Graz (Med Uni Graz), Austria\n* the University of Graz, Austria\n* the Red Cross\n* the Police\n* Fire brigade of the city of Graz\n\nExclusion Criteria:\n\n* Pregnancy, allergy against latex or PVC, claustrophobia, acute infection, thrombophilia\n* Chronic illnesses (not treated) such as asthma, COPD, cardiovascular diseases, diabetes mellitus and epilepsy,\n* Participation in another study",{"count":129,"type":23},12,[53],"The purpose of this pilot study is to improve protection of first responders in case of biological disasters (e.g., pandemics, biotoxin incidents). For this goal we will compare two different kinds of personal protective equipment (PPE) to be used for a variety of exercises simulating activities of first responders in the field at two different environmental temperature profiles in a randomized cross-over study design. The goal is to find the best possible compromise between protection and ergonomics as well as to determine potential factors that might limit the performance of first responders while wearing PPE. This should provide guidance for future improvement of PPE and how biosensors for monitoring heart rate and body temperature in combination with AI models may reduce risk for first responders in the field.",[29],[134,135,136,137],"Personal protective equipment","physiological parameters","biosensor","first responder","2026-07-21",{"date":140,"type":34},"2026-07-24",{"date":142,"type":34},"2026-07-17",{"date":144,"type":23},"2027-01",{"name":146,"class":76},"Medical University of Graz",{"id":148,"slug":149,"hasResults":12,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":17,"sex":18,"minAge":154,"maxAge":155,"enrollmentInfo":156,"targetDuration":4,"studyType":24,"phases":158,"briefSummary":160,"conditions":161,"keywords":162,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":172,"leadSponsor":174,"locationsCount":42},"100648008","early-phase-1-ivabradine-for-heart-rate-reduction-during-exercise-in-healthy-adults-100648008","NCT07717710","Ivabradine for Heart Rate Reduction During Exercise in Healthy Adults","Heart Rate Reduction Via Oral Ivabradine During Exercise in Healthy Adults to Understand Heart Rate\u002FWork-rate Relations: A Pilot Dose-selection Study","Inclusion Criteria:\n\n* Healthy males and females aged 19-39 years, and 60-79 years\n* Engaging in regular aerobic exercise (e.g., running, cycling, swimming, hiking, field, ice, or racquet sports) at least once per week\n\nExclusion Criteria:\n\n* History of any cardiovascular condition, including hypertension\n* Use of any chronic medication\n* History of any respiratory condition, including asthma\n* Smoking, including cannabis or vaping in the past year\n* History of diabetes mellitus, cancer, hepatic, renal or any other chronic illness\n* Seated blood pressure ≥130\u002F90 or \\\u003C100\u002F60 mmHg\n* Body mass index \\\u003C20 or \\>32 kg\u002Fm2\n* Non-sinus rhythm or abnormalities on 12-lead electrocardiogram (ECG)\n* Pregnant, breastfeeding, or women of childbearing potential not using appropriate contraception\n* Current or recent (past year) participation in \\>150 minutes per week of moderate-vigorous intensity exercise (to avoid endurance training-related bradycardia)\n* Any condition that prevents vigorous exercise from being performed safely\n* Seated resting heart rate \\\u003C60 beats per minute\n* Prolonged QT interval (e.g., long QT syndrome)\n* Sick sinus syndrome, sino-atrial block or third-degree atrio-ventricular block\n* Use of strong cytochrome P450 (CYP3A4) inhibitors (e.g., nirmatrelvir and ritonavir, ketoconazole), which can increase ivabradine levels in the blood to potentially unsafe levels\n* Use of verapamil or diltiazem, which are moderate CYP3A4 inhibitors and also lower heart rate, posing a risk of excessive bradycardia when combined with ivabradine\n* Lactose intolerance, as ivabradine contains lactose\n* Known allergy\u002Fhypersensitivity to ivabradine or to any ingredient in the formulation or component of the container","19 Years","79 Years",{"count":157,"type":23},20,[159],"EARLY_PHASE1","During exercise, working muscles require more oxygen. The heart meets this demand in two ways: by beating faster (heart rate) and by pumping more blood with each beat (stroke volume). Heart rate increases steadily with exercise intensity until exhaustion, but the amount of blood pumped with each beat tends to plateau at moderate intensities. Why the amount of blood pumped with each beat becomes limited before heart rate, however, is not well understood.\n\nStudying these mechanisms is difficult because most drugs that lower heart rate also affect how strongly the heart pumps, making it hard to separate the two effects. One medication that can help with this is ivabradine, which is used to treat people with heart disease who have high resting heart rates. It slows the heart rate without changing how strongly the heart pumps.\n\nThis study will investigate whether ivabradine lowers heart rate during exercise in healthy younger and older adults, and whether a higher dose lowers heart rate more. The results will help us better understand how heart rate influences the heart's ability to supply oxygen to the body during exercise, and what limits the ability to exercise as people age.\n\nParticipants will:\n\n* Attend three visits at SportsCardiologyBC in Vancouver\n* Complete a cycling exercise test at each visit to measure heart rate and how hard they can exercise\n* Take ivabradine (a heart-rate-lowering medication) before the exercise test at Visits 2 and 3 (a lower dose at Visit 2 and a higher dose at Visit 3)\n* Be monitored for side effects including slow heart rate, visual symptoms, and headache.",[29],[163,164,165,166,167],"Heart rate regulation","Stroke volume","Cardiac output","Exercise","Exercise capacity","2026-07-20",{"date":170,"type":34},"2026-07-22",{"date":92,"type":23},{"date":173,"type":23},"2026-12",{"name":175,"class":76},"University of British Columbia",{"id":177,"slug":178,"hasResults":12,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":183,"enrollmentInfo":184,"targetDuration":4,"studyType":24,"phases":186,"briefSummary":187,"conditions":188,"keywords":194,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":42},"100648165","comparison-between-eccentric-hamstring-training-and-sprint-specific-training-100648165","NCT07716319","Comparison Between Eccentric Hamstring Training and Sprint-Specific Training","Comparison Between Eccentric Hamstring Strength Training and Sprint-Specific Training on Muscle Hypertrophy, Strength, Power, and Sprint Performance in Club Sport Collegiate Athletes","Inclusion Criteria:\n\n* Age 18-25 years\n* Actively participating in a club team\n* \\>6 months experience with resistance training\n* Minimum of 1 year experience at the high school level in organized team sport\n* No history of hamstring injury within the last 6 months\n* No history of major lower extremity surgery (including back)\n* No acute musculoskeletal injury to the lower extremity\n* Not currently pregnant\n\nExclusion Criteria:\n\n* Unable to refrain from resistance training outside the study\n* Unable to make at least 80% of the training sessions\n* Hamstring injury in the last 6 months\n* History of major lower extremity surgery (including back)\n* Acute musculoskeletal injury to the lower extremity\n* Currently pregnant","25 Years",{"count":185,"type":23},90,[53],"The purpose of this study is to compare the effects of an intensity-, volume-, and time under tension-matched eccentric hamstring exercise intervention with the Romanian deadlift (RDL) and the Nordic hamstring exercise (NHE) to a sprint-specific training program on hamstring muscle architecture, volume, sprint performance, strength, and power.\n\nParticipants will be assigned to complete one of the 3 hamstring interventions for 10 weeks.",[29,189,190,191,192,193],"Athlete","Exercise Training","Sport","Running","Ultrasound Imaging",[195,196,197,198,199,200,201,202],"strength","agility","sprint","hypertrophy","countermovement jump","fascicle length","hamstring","range of motion","2026-07-15",{"date":138,"type":34},{"date":206,"type":23},"2026-09",{"date":208,"type":23},"2027-09",{"name":210,"class":76},"University of Wisconsin, Madison",{"id":212,"slug":213,"hasResults":12,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":4,"eligibilityCriteria":217,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":183,"enrollmentInfo":218,"targetDuration":4,"studyType":24,"phases":219,"briefSummary":220,"conditions":221,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":224,"completionDateStruct":225,"leadSponsor":227,"locationsCount":42},"100647612","diurnal-strength-variation-100647612","NCT07711340","Diurnal Strength Variation","Exercise Timing and Lower Limb Biomechanics","Inclusion Criteria:\n\n* Healthy\n* 18-25 years old\n* Lower body exercise three or more times per week, all at the same time of day (within 2 hour window)\n* Regular meal times (±1 hour window)\n* Regular sleep times (±1 hour window)\n\nExclusion Criteria:\n\n* Active or uncontrolled mental or physical health issues\n* Current musculoskeletal injury",{"count":157,"type":23},[53],"Healthy individuals will be tested at different times of day to determine whether exercise at a non-expected time results in poorer performance.",[29,166],"2026-07-14",{"date":142,"type":34},{"date":92,"type":23},{"date":226,"type":23},"2026-12-31",{"name":228,"class":76},"Stanford University",{"id":230,"slug":231,"hasResults":12,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":4,"eligibilityCriteria":235,"healthyVolunteers":17,"sex":18,"minAge":236,"maxAge":20,"enrollmentInfo":237,"targetDuration":4,"studyType":24,"phases":238,"briefSummary":239,"conditions":240,"keywords":242,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":4},"100647685","diaplex-and-glycemic-control-100647685","NCT07711587","Diaplex and Glycemic Control","A Pilot Study Investigating the Effects of Diaplex Supplementation on Glucose Regulation in Otherwise Healthy Adults With Elevated Blood Glucose Levels","Inclusion Criteria • Adults 30-65 years old with elevated average blood glucose levels (100-125 mg\u002FdL), confirmed at screening (HbA1c 5.7-6.4%)\n\n• BMI 18.5-29.9 kg\u002Fm² (normal to overweight)\n\n• Generally healthy individuals with no metabolic or endocrine disorders besides elevated blood glucose levels, meaning no metabolic syndrome, insulin resistance diagnosis, dyslipidemia diagnosis requiring treatment, thyroid disorders, etc.\n\n• Stable weight for the past 3 months (±5%)\n\n• Sedentary or lightly active baseline lifestyle (Light activity ≤3 times\u002Fweek (e.g., walking, yoga, casual biking)\n\n• Willingness to maintain usual diet, activity, and sleep patterns for 16 weeks\n\n• Able and willing to wear a CGM for the final 10-14 days\n\n• Willing to complete 3-day dietary recalls, sleep and activity logs\n\n• Not taking or willing to stop taking supplements containing chromium, vitamin A, vitamin B6, iodine, and niacin\n\n• Able and willing to provide informed consent and complete all study visits 6 Exclusion Criteria\n\n• Any diagnosed metabolic\u002Fendocrine disorder, other than elevated blood glucose levels, such as metabolic syndrome, insulin resistance diagnosis, clinically significant dyslipidemia, thyroid dysfunction or use of thyroid medication, or obesity-related endocrine dysfunction\n\n• Medications and supplements use of glucose-lowering medications within the past 3 months, including use of weight-loss drugs or metabolic agents, such asGLP-1 RAs (Ozempic, Wegovy, Rybelsus, Trulicity, Victoza, Saxenda) or GIP\u002FGLP-1 RAas (Mounjaro, Zepbound)\n\n• Use of supplements within the last 30 days containing chromium, vitamin A, vitamin B6, niacin, iodine\n\n• Unwilling to discontinue prohibited supplements\n\n• Health Conditions \\& safety such as elevated ALT\u002FAST more than 2× the upper limit or known chronic liver disease or diagnosed renal impairment (eGFR \\\u003C45 mL\u002Fmin\u002F1.73 m²), uncontrolled hypertension (\\>160\u002F100 mmHg)\n\n• Pregnant, breastfeeding, or planning pregnancy\n\n• Allergy or sensitivity to study ingredients or CGM adhesives\n\n• Lifestyle and compliance (\\>30 minutes\u002Fday of intense physical activity (active adults or athletes))\n\n• Participation in another investigational trial in the past 30 days\n\n• Any condition that may interfere with participation or data quality (per investigator guidance)","30 Years",{"count":107,"type":23},[53],"The goal of this 16-week double-blind, placebo-controlled pilot study is to determine whether daily Diaplex supplementation improves insulin sensitivity and glycemic control in adults with elevated blood glucose levels, while generating high-quality preliminary data on metabolic effects, glycemic patterns, and safety to inform future trials",[241,29],"Insulin Sensitivity",[243,244,245],"Supplement","Chromium","Glycemic Index","2026-07-13",{"date":142,"type":34},{"date":249,"type":23},"2026-09-01",{"date":251,"type":23},"2027-12-15",{"name":253,"class":41},"Standard Process Inc.",{"id":255,"slug":256,"hasResults":12,"nctId":257,"briefTitle":258,"officialTitle":259,"acronym":4,"eligibilityCriteria":260,"healthyVolunteers":17,"sex":18,"minAge":105,"maxAge":155,"enrollmentInfo":261,"targetDuration":4,"studyType":24,"phases":263,"briefSummary":264,"conditions":265,"keywords":266,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":271,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":42},"100620729","sweetspot---the-effect-of-non-nutritive-sweeteners-on-health-100620729","NCT07361406","SweetSpot - The Effect of Non-nutritive Sweeteners on Health","SweetSpot - The Effect of Non-nutritive Sweeteners on Glucose Regulation, Gut Microbiome, and Gut Hormone Secretion in Healthy Adults: a Fully Controlled Cross-over Intervention Study","Inclusion Criteria:\n\n* Age 45-79 years;\n* BMI of 20-35 kg\u002Fm2;\n* Having veins suitable for placement of a venflon catheter.\n\nExclusion Criteria:\n\n* Diseases or prior surgeries affecting the stomach, liver, kidneys or intestines (allowed i.e. appendectomy);\n* Cardiovascular diseases (e.g. heart failure) or cancer (e.g. non-invasive skin cancer allowed);\n* Diagnosed with type 1 or type 2 diabetes;\n* Drug treated thyroid diseases (well substituted hypothyroidism is allowed for inclusion);\n* HbA1c level \\>6.5% (\\>48 mmol\u002Fmol), as measured during the screening visit;\n* Anaemia defined as Hb concentrations \\\u003C8.5 mmol\u002FL for men and \\\u003C7.5 mmol\u002FL for women via finger prick;\n* Regular use of\u002Freceiving medication interfering with research outcomes (as judged by research physician), such as use of glucose lowering drugs, insulin, or use of medication that impacts the gastro-intestinal system;\n* Use of antibiotics over the last 3 months before study start;\n* Donated blood within 2 months prior to the screening;\n* Food allergies, intolerances (including lactose\u002Fgluten intolerance) for products used in the study design and\u002For dietary restrictions interfering with the study (including special diets and eating disorders);\n* Followed a diet that can interfere with the study outcomes within 1 month prior to the screening (e.g. ketogenic, sugar free, carbohydrate free);\n* Not willing to eat all products in the study diet, including eggs and dairy. Vegetarian is possible;\n* Not willing to consume non-nutritive sweeteners;\n* Not willing to quit the use of supplements that can interfere with the study outcomes (e.g. pre- or probiotics).\n* Intention to change the intensity of exercise during the study period or planning to join a intensive sport event (e.g. marathon or triathlon);\n* Intention to lose or gain weight;\n* Working night shifts regularly;\n* Smoking regularly\n* Use of soft and\u002For hard drugs (cannabis included);\n* Abuse of alcohol (defined as \\>14 glasses (women) or \\>21 glasses (men) of alcoholic beverages per week);\n* Being pregnant or lactating or planning to become pregnant;\n* Inability to understand study information and\u002For communicate with staff;\n* Participation in another study that involves an intervention within two months prior to the intervention;\n* Working or doing a thesis\u002Finternship at the division of Human Nutrition \\& Health, or the Food, Health \\& Consumer Research group of Wageningen Food \\& Biobased Research.",{"count":262,"type":23},60,[53],"The aim of the study is to investigate the effect of non-nutritive sweeteners on glucose regulation. Secondary objectives are to investigate the effect of NNS on gut microbiome, gut hormone secretion, sweet taste sensitivity and preference, and the excretion of NNS in urine.",[29],[267,268,269,270],"glucose metabolism","gut microbiome","gut hormones","non-nutritive sweeteners",{"date":222,"type":34},{"date":273,"type":34},"2026-02-23",{"date":275,"type":23},"2027-03-26",{"name":277,"class":76},"Wageningen University",{"id":279,"slug":280,"hasResults":12,"nctId":281,"briefTitle":282,"officialTitle":282,"acronym":4,"eligibilityCriteria":283,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":284,"targetDuration":4,"studyType":24,"phases":286,"briefSummary":287,"conditions":288,"keywords":289,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":293,"completionDateStruct":294,"leadSponsor":296,"locationsCount":42},"100645668","effect-of-monosodium-glutamate-on-microbiome-derived-imidazole-propionate-production-in-healthy-volunteers-100645668","NCT07700368","Effect of Monosodium Glutamate on Microbiome-Derived Imidazole Propionate Production in Healthy Volunteers","Inclusion Criteria:\n\n* Age 18 years or older\n* No antibiotic use in the previous 3 months\n\nExclusion Criteria:\n\n* Diagnosis of diabetes or prediabetes (any type)\n* Inflammatory bowel disease or other gastrointestinal disorder\n* Known allergy or intolerance to monosodium glutamate (MSG)\n* Pregnancy or breastfeeding\n* Current participation in another clinical trial\n* High habitual dietary intake of MSG or histidine",{"count":285,"type":23},18,[53],"The goal of this clinical trial is to learn whether dietary monosodium glutamate (MSG), a common food flavor enhancer, increases the blood level of a gut-microbiome-derived compound called imidazole propionate (ImP) in healthy adult volunteers. ImP is a compound made by gut bacteria from the amino acid histidine, and higher blood levels have been linked to problems with blood-sugar control. The main questions this trial aims to answer are:\n\nDoes taking MSG together with L-histidine increase blood ImP levels compared with taking a salt (sodium chloride) placebo together with L-histidine? How do blood ImP levels change over time in response to MSG and L-histidine taken together?\n\nResearchers will compare a 7-day period of L-histidine plus MSG against a 7-day period of L-histidine plus sodium chloride (a salt placebo with matching sodium content) to see whether MSG changes blood ImP levels. Each participant completes both periods in random order and serves as their own comparison.\n\nParticipants will:\n\nTake L-histidine capsules twice daily (morning and evening with meals) during two separate 7-day periods.\n\nDissolve either MSG powder or salt powder in water and drink it twice daily during each period, with the two periods separated by a 7-day break (washout).\n\nGive a fasting blood sample at the start of the study and on day 7 of each period.\n\nOptionally provide a stool sample at the end of each period. Complete a daily treatment diary and a follow-up phone call after the final sample.",[29],[290],"Monosodium glutamate","2026-07-08",{"date":222,"type":34},{"date":203,"type":23},{"date":295,"type":23},"2027-12-31",{"name":297,"class":76},"University of Chicago",{"id":299,"slug":300,"hasResults":12,"nctId":301,"briefTitle":302,"officialTitle":303,"acronym":304,"eligibilityCriteria":305,"healthyVolunteers":17,"sex":18,"minAge":306,"maxAge":307,"enrollmentInfo":308,"targetDuration":4,"studyType":24,"phases":310,"briefSummary":311,"conditions":312,"keywords":314,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":318,"startDateStruct":320,"completionDateStruct":322,"leadSponsor":324,"locationsCount":42},"100644409","finding-immune-nascent-type-1-diabetes-100644409","NCT07663136","Finding Immune Nascent Type 1 Diabetes","Finding Immune Nascent Type 1 Diabetes (FIND T1D)","FIND T1D","Inclusion Criteria:\n\n* Participant must be in Indiana Biobank\n* Participant must be able to provide consent\n* Ages 1-99 including pregnant women\n\nExclusion Criteria:\n\n* Refusal to sign informed consent for home screening is exclusionary for the home screening portion of the study\n* While other medical conditions are allowable prior diabetes diagnosis is exclusionary for home autoantibody screening","1 Year","99 Years",{"count":309,"type":23},3800,[53],"The goal of this clinical trial is to understand how many individuals who previously participated in the Indiana Biobank will return a type 1 diabetes home screening kit based upon different methods of recruitment communication. The main question it aims to answer is:\n\nWhat form of recruitment communication is most effective for completing a type 1diabetes home screening kit?\n\nResearchers will compare two types of recruitment contact: email and mail based communication (low-touch) versus phone contact and follow-up by a research team member (high-touch).\n\nParticipants will be contacted either via email\u002Fmail or by phone and asked if they want to complete a type 1 diabetes home screening kit.",[29,313],"Type 1 Diabetes (T1D)",[315,316],"type 1 diabetes home screening kit","type 1 diabetes","2026-06-17",{"date":319,"type":34},"2026-06-23",{"date":321,"type":23},"2026-06",{"date":323,"type":23},"2029-06",{"name":325,"class":76},"Indiana University",{"id":327,"slug":328,"hasResults":12,"nctId":329,"briefTitle":330,"officialTitle":331,"acronym":4,"eligibilityCriteria":332,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":333,"targetDuration":4,"studyType":24,"phases":335,"briefSummary":336,"conditions":337,"keywords":338,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":346,"startDateStruct":347,"completionDateStruct":348,"leadSponsor":350,"locationsCount":42},"100641658","nicotinamide-riboside-vit-b3-analogue-and-brain-energy-metabolism-100641658","NCT07649161","Nicotinamide Riboside, Vit B3 Analogue, and Brain Energy Metabolism","The Effects of Nicotinamide Riboside Supplementation on Brain NAD+\u002FNADH Ratio and Bioenergetics","Inclusion Criteria:\n\n1. Adults (between 18 and 65 years old)\n2. Without a current psychiatric diagnosis assessed by a structured psychiatric interview at the screening\u002Fconsent visit\n3. Without a history of a psychotic disorder and\u002For mood disorder among parents, siblings, or children\n\nExclusion Criteria:\n\n1. Any current significant medical or neurological illness.\n2. Diagnosis of diabetes mellitus (DM), uncontrolled hypertension (HTN), severe hypotension, coronary artery disease (CAD), metabolic syndrome, glaucoma, liver impairment, decreased renal function, respiratory disorders, and uncontrolled peptic ulcer disease.\n3. Currently taking any other medications, including over-the-counter supplements except oral contraceptives for women and Tylenol as needed for pain or headache.\n4. Currently pregnant or breastfeeding. Females of child-bearing age must be using an effective contraceptive method.\n5. History of substance abuse or dependence.\n6. Contraindication to MR scan (claustrophobia, cardiac pacemakers, metal clips and stents on blood vessels, artificial heart valves, artificial arms, hands, legs, etc., brain stimulator devices, implanted drug pumps, ear implants, eye implants or known metal fragments in eyes, exposure to shrapnel or metal filings, other metallic surgical hardware in vital areas, certain tattoos with metallic ink, certain transdermal patches, metal- containing IUDs)\n7. Medical condition that would prevent blood draws, including current anti-coagulant or anti-aggregant therapy, tendency for abnormal scarring (e.g., keloids).\n8. Difficulty in swallowing capsules.",{"count":334,"type":23},50,[53],"The goal of this clinical trial is to learn how nicotinamide riboside (NR), a form of vitamin B3, affects brain energy metabolism in healthy adults. Researchers want to find out if taking NR by mouth for 2 weeks can raise the balance of two related brain chemicals called NAD+ and NADH, which play a key role in how cells make and use energy. The main questions are: Does short term NR treatment increase the NAD+ to NADH ratio in the brain, and does it change other brain energy measures that we can see with a special type of MRI scan called phosphorus 31 MR spectroscopy.\n\nAdults between 18 and 65 years old who are generally healthy and do not have a personal or close family history of mood or psychotic disorders may be able to take part. People who join the study will first have a screening visit with a psychiatric interview and safety checks to confirm they are eligible and to review the risks and procedures. Eligible participants will then have a baseline visit that includes a blood draw, vital signs, urine drug and pregnancy tests when needed, and a 7 Tesla MRI\u002FMRS scan focused on brain chemistry and structure.\n\nAfter the baseline visit, participants will take NR capsules by mouth at home, 1500 milligrams in the morning and 1500 milligrams in the early afternoon each day, for about 2 weeks, for a total daily dose of 3000 milligrams. They will be asked to avoid alcohol and other drugs during the study and to complete a short food diary near the end of the dosing period so that researchers can track diet. On the last day of taking NR, participants will return for repeat MRI\u002FMRS scans, blood tests, and vital signs so that researchers can compare brain and blood measures before and after NR treatment.\n\nResearchers will compare each participant's brain NAD+ to NADH ratio and other bioenergetic markers before and after NR to see if NR changes these measures in a consistent way. If NR raises brain NAD+ and improves measures of energy metabolism in healthy adults, this may provide important background information for future studies that test whether NR can help people with psychiatric or neurological disorders linked to mitochondrial dysfunction and oxidative stress. There is no expected direct health benefit for participants, but their involvement may help improve understanding of how NR affects human brain metabolism.",[29],[339,340,341,342,343,344],"Nicotinamide riboside supplementation","Vitamin B3 analogs","Nicotinamide adenine dinucleotide metabolism","Brain energy metabolism","Phosphorus 31 magnetic resonance spectroscopy","Brain bioenergetics imaging","2026-06-15",{"date":317,"type":34},{"date":321,"type":23},{"date":349,"type":23},"2028-01",{"name":351,"class":76},"Massachusetts General Hospital",{"id":353,"slug":354,"hasResults":12,"nctId":355,"briefTitle":356,"officialTitle":356,"acronym":357,"eligibilityCriteria":358,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":359,"enrollmentInfo":360,"targetDuration":4,"studyType":362,"phases":4,"briefSummary":363,"conditions":364,"keywords":367,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":377,"lastUpdatePostDateStruct":378,"startDateStruct":380,"completionDateStruct":381,"leadSponsor":382,"locationsCount":4},"100641671","ultrasound-muscle-biomarkers-as-predictors-of-isometric-quadriceps-muscle-strength-and-handgrip-in-healthy-adults-an-observational-study-100641671","NCT07647393","Ultrasound Muscle Biomarkers as Predictors of Isometric Quadriceps Muscle Strength and Handgrip in Healthy Adults: an Observational Study","MUSCLE-US","Inclusion Criteria:\n\n* Healthy adults aged 18-89 years.\n* Resident in Spain for at least 5 years.\n* Living independently in the community and able to complete all study assessments.\n* Able to understand and follow verbal instructions in Spanish.\n* Able and willing to provide written informed consent prior to study participation.\n\nExclusion Criteria:\n\n* Neurological, musculoskeletal, or systemic disorders affecting muscle strength or mobility.\n* Recent surgery or acute injury affecting the upper or lower limbs.\n* Recent use of medications affecting the musculoskeletal system (e.g., systemic corticosteroids for \\>1 week during the previous 6 months or muscle relaxants during the previous week).\n* Cognitive or psychiatric conditions limiting participation.\n* Pregnancy.\n* Recent postpartum period (≤3 months after delivery).\n* Presence of clinically relevant pain, fatigue, physical deconditioning, or functional limitations that may interfere with study procedures or measurement validity.\n* Acute illness at the time of assessment.\n* Uncontrolled hypertension (≥140\u002F90 mmHg).\n* Resting peripheral oxygen saturation ≤90%.\n* Moderate-to-severe pain (Numeric Rating Scale ≥4\u002F10).\n* Any medical condition considered by the investigator to contraindicate study participation.","89 Years",{"count":361,"type":23},300,"OBSERVATIONAL","This observational study aims to determine whether ultrasound-derived muscle biomarkers can predict isometric quadriceps muscle strength and handgrip in healthy adults aged 18-89 years.\n\nThe main questions it aims to answer are:\n\n* Which ultrasound muscle characteristics are associated with isometric quadriceps muscle strength and handgrip?\n* Can ultrasound-derived biomarkers be used to develop predictive models of muscle strength in healthy adults?\n\nParticipants will undergo:\n\n* Ultrasound assessment of the quadriceps and forearm flexor muscles;\n* Measurement of isometric quadriceps muscle strength and handgrip using standardized dynamometry protocols;\n* Assessment of functional capacity, mobility and balance;\n* Completion of questionnaires related to health status, physical activity, nutrition, fatigue and health-related quality of life.\n\nThe study will also assess the reliability of ultrasound measurements and explore the relationship between ultrasound variables, muscle strength, physical function and health-related factors.",[29,365,366],"Muscle Strength","Skeletal Muscle Ultrasound",[368,369,370,371,372,373,374,375,376],"Muscle ultrasound","Skeletal muscle ultrasonography","Muscle biomarkers","Isometric quadriceps muscle strength","Handgrip","Muscle thickness","Echo intensity","Muscle quality","Predictive models","2026-06-12",{"date":379,"type":34},"2026-06-16",{"date":321,"type":23},{"date":323,"type":23},{"name":383,"class":76},"University of Alcala",{"id":385,"slug":386,"hasResults":12,"nctId":387,"briefTitle":388,"officialTitle":389,"acronym":4,"eligibilityCriteria":390,"healthyVolunteers":17,"sex":18,"minAge":391,"maxAge":392,"enrollmentInfo":393,"targetDuration":4,"studyType":24,"phases":394,"briefSummary":396,"conditions":397,"keywords":399,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":413,"lastUpdatePostDateStruct":414,"startDateStruct":415,"completionDateStruct":417,"leadSponsor":419,"locationsCount":42},"100633481","phase-2-improving-vaccine-protection-for-adults-100633481","NCT07527247","Improving Vaccine Protection for Adults","Using AS01 Adjuvant to Improve Immune Response in Older Adults Through Trained Immunity","Inclusion Criteria:\n\n* Adults aged 21 to 59 years of age at time of screening.\n* BMI 18.5 - 27.5 kg \u002F m2 (BMI values for Asian population according to MOH guideline NIH Consensus Conference).\n* Satisfactory baseline medical assessment as assessed by physical examination and a stable health status. For subjects with underlying comorbidities, the conditions must be deemed stable by the investigators, and they must not have any hospitalisation relating to these conditions in the last 6 months.\n* Voluntarily participate, understand and sign an informed consent form approved by the Ethical Review Board.\n* Subjects who are willing to comply with the requirements of the study protocol and scheduled visits. These requirements include completion of the subject diary, return for follow-up visits. Subjects should also be willing to make themselves available for the duration of the study, with access to a consistent means of contact.\n* Accessible vein at the forearm for blood taking.\n* Female subjects of non-childbearing potential due to surgical sterilisation (hysterectomy or bilateral oophorectomy or tubal ligation) or menopause. Post-menopausal subjects must have had at least 12 months of natural (spontaneous) amenorrhoea.\n\nExclusion Criteria:\n\n* Previous vaccination against yellow fever, dengue either with a registered product or from participation in a previous vaccine study.\n* Previously received AS01-adjuvanted vaccines (e.g. Recombinant zoster vaccine, RTS,S\u002FAS01, RSVPre-F3-AS01), either with a registered product or from participation in a previous vaccine study.\n* Planned administration of a AS01-adjuvanted vaccine or yellow fever vaccine other than the study vaccine during the study.\n* Subjects who have been unwell in the last 7 days prior to screening.\n* History of documented yellow fever and \u002F or dengue infection.\n* Dengue seropositivity upon screening.\n* History of smoking within the last 1 year.\n* Planned travel to yellow fever endemic countries during the study.\n* Known allergy to AS01 and YF17D vaccine or their components (e.g. egg products).\n* Diagnosis of diabetes HBA1c \\> 6.5 according to American Diabetes Association criteria62.\n* Any medical condition that in the judgment of the investigator will make intramuscular injection unsafe (e.g. thrombocytopenia with platelet count \\\u003C 50x10\\^9\u002FL, coagulopathy, anti-coagulant therapy).\n* Risk factor for live-attenuated vaccines, including any confirmed or suspected primary or acquired immunodeficiency based on history and physical examination:\n\n  * History of thymus gland disease\n  * Haematologic neoplasms including leukaemia, lymphoma, myelodysplastic syndromes\n  * Diagnosed with cancer or treatment for cancer (except for localised basal cell carcinoma) within 3 years prior to screening\n  * Post-transplant: solid organ and haematopoietic stem cell transplant\n  * Immunocompromised due to primary or acquired (including HIV\u002FAIDS) immunodeficiency\n  * Other significantly immunocompromising conditions\n* Administration of anti-inflammatory drugs for the past 7 days (e.g. NSAIDs, Paracetamol, aspirin).\n* Use of metformin for the last 1 month.\n* Use of corticosteroids within the last 6 months prior to the first vaccine dose (defined as prednisolone \\> 10 mg \u002F day or equivalent for \\> 2 weeks, or prednisolone \\> 40mg \u002F day or \\> 1 week). Inhaled and topical steroids are allowed.\n* Received biologics (such as anti-TNF inhibitors, IL-1 inhibitors, co-stimulation blockers, B-cell depleting therapy) for the last 12 months.\n* Any condition (e.g. extensive psoriasis, chronic pain syndrome, severe hearing loss, cognitive impairment, dialysis, autoimmune disorders) that in the opinion of the investigator, would complicate or compromise the study or wellbeing of the subject, or prevent completion of the study.\n* Evidence of substance abuse, or previous substance abuse.\n* Clinically significant anaemia (Hb \\\u003C 10 g\u002FdL).\n* Blood donation exceeding \\> 450 ml in the past 3 months.\n* Participation in a study involving administration of an investigational or non-investigational compound within the past four months or planned participation during the duration of this study.\n* Administration of any licensed vaccine within 30 days before the first study vaccine dose or planned to receive such products within 30 days after the study vaccination.\n* Received immunoglobulin or any blood products within the 90 days preceding the first dose of study vaccine or planned to receive such products during the study period.","21 Years","59 Years",{"count":107,"type":23},[395],"PHASE2","As people grow older, their immune system - the body's natural defence against diseases - becomes weaker, making them more vulnerable to infections and less responsive to vaccines. This was clearly seen during the COVID-19 pandemic, where older adults were more likely to develop severe illness. Researchers have made an interesting discovery about AS01, an ingredient already used in successful vaccines like the shingles vaccine. They found clues that AS01 might work like a general fitness trainer for the immune system, potentially making it stronger and better at fighting off various types of infections, not just specific ones. To confirm this possibility, we are conducting this research study with adults aged 21-59 to test whether AS01 by itself can boost and train the immune system, how long this boost lasts, and if it actually helps you fight off other infections more effectively.",[398,29],"Immune System Responses and Trained Immunity After AS01 Administration",[400,401,402,403,404,405,406,407,408,409,410,411,412],"AS01","AS01 adjuvant","Immune durability","Immune system","Immune response modulation","Recombinant zoster vaccine adjuvant","Vaccine","Randomized","Placebo-controlled","Blinded","Healthy volunteers","Protective effects","Yellow Fever Vaccine","2026-06-11",{"date":345,"type":34},{"date":416,"type":34},"2025-11-06",{"date":418,"type":23},"2029-02-28",{"name":420,"class":76},"Singapore General Hospital",{"id":422,"slug":423,"hasResults":12,"nctId":424,"briefTitle":425,"officialTitle":426,"acronym":4,"eligibilityCriteria":427,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":428,"targetDuration":4,"studyType":24,"phases":429,"briefSummary":430,"conditions":431,"keywords":432,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":438,"startDateStruct":439,"completionDateStruct":440,"leadSponsor":442,"locationsCount":4},"100624057","safety-and-effects-of-high-intensity-blood-flow-restriction-training-in-the-rotator-cuff-100624057","NCT07404683","Safety and Effects of High-Intensity Blood Flow Restriction Training in the Rotator Cuff","Safety, Utility and Effects After 8 Weeks of High-intensity Strength Training With Blood Flow Restriction in the Rotator Cuff","Inclusion Criteria:\n\n* Healthy, untrained adults\n* Age between 18 and 65\n\nExclusion Criteria:\n\n* Current participation in an upper limb strength training program\n* Presence of comorbidities that increase cardiovascular risk (uncontrolled ischemic heart disease, uncontrolled hypertension, diabetes, etc.)\n* Patients with more than one thromboembolism risk factor (obesity, history of thrombosis, prolonged immobilization, recent surgery, use of contraceptives, etc.)\n* Current diagnosis of any pathology affecting the cervical spine, shoulder, and\u002For thoracic spine\n* History of surgery in the last year\n* Use of ergogenic aids or medications that affect muscle metabolism (anabolic steroids, testosterone, creatine, protein supplements, corticosteroids, chronic use of nonsteroidal anti-inflammatory drugs, etc.)",{"count":262,"type":23},[53],"This study aims to analyze the effects of an 8-week strength training program combining different exercise intensities and blood flow restriction (BFR) conditions on safety, tolerability, muscle adaptations, and physical performance variables. Three training modalities will be compared: 1) high-intensity exercise with BFR therapy; 2) low-intensity exercise with BFR therapy; and 3) high-intensity exercise without BFR therapy. All groups will perform the same exercise modality, differing only in intensity and the application of BFR.\n\nParticipants will be randomly assigned to one of the three groups and will undergo a 8-week intervention. The variables of interest will be assessed in each group for subsequent analysis and comparison.",[29],[433,434,435,436],"blood flow restriction","exercise","high-intensity","rotator cuff","2026-06-08",{"date":413,"type":34},{"date":206,"type":23},{"date":441,"type":23},"2028-06",{"name":443,"class":76},"University of Valencia",{"id":445,"slug":446,"hasResults":12,"nctId":447,"briefTitle":448,"officialTitle":448,"acronym":449,"eligibilityCriteria":450,"healthyVolunteers":17,"sex":18,"minAge":451,"maxAge":452,"enrollmentInfo":453,"targetDuration":4,"studyType":24,"phases":455,"briefSummary":456,"conditions":457,"keywords":460,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":466,"lastUpdatePostDateStruct":467,"startDateStruct":469,"completionDateStruct":471,"leadSponsor":473,"locationsCount":42},"100642604","early-phase-1-evaluation-of-fmodag-009-pet-imaging-in-synucleinopathies-100642604","NCT07640555","Evaluation of [¹⁸F]MODAG-009 PET Imaging in Synucleinopathies","MODAG-009-P1-0","Inclusion Criteria:\n\n* Healthy Controls inclusion criteria:\n\n  1. Enrolled in the PPMI 002 Clinical study as a healthy control participant\n  2. Any gender aged 50 to 75 years of age\n  3. Negative CSF α-synuclein seed amplification assay (SAA)\n  4. Previously acquired (since inclusion in PPMI) brain MRI without evidence of significant neurological pathology.\n  5. Movement Disorders Society- Unified Parkinson's Disease Rating Scale Part III (MDS-UPDRS III) score of \\\u003C6 at the last PPMI annual visit which is within the past 18 months.\n  6. Cognitively intact with Montreal Cognitive Assessment (MoCA) greater than or equal to 26 at the last PPMI annual visit which was within the past 18 months.\n* Parkinson's Disease and Prodromal PD inclusion criteria:\n\n  1. Enrolled in the PPMI 002 Clinical study as a Parkinson's Disease (PD) or Prodromal participant\n  2. Any gender aged 50 to 80 years of age\n  3. Positive CSF SAA\n  4. A current or previously acquired brain MRI (since the onset of motor symptoms for PD or since enrolled in PPMI for the prodromal PD) without evidence of significant neurological pathology other than changes expected for PD.\n  5. Montreal Cognitive Assessment (MoCA) greater than or equal to 24 at the last PPMI annual visit which was within the past 18 months.\n* Multiple System Atrophy (MSA) inclusion criteria:\n\n  1. Any gender aged 50 to 75 years of age\n  2. Clinically established MSA or Clinically Probable MSA according to the Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy (Wenning et al., 2022)\n  3. Positive CSF SAA\n  4. A current or previously acquired brain MRI (since the onset of motor symptoms attributed to MSA) without evidence of significant neurological pathology other than the pathology expected for MSA.\n  5. Evidence of nigrostriatal degeneration on DaTscan obtained at screening or on previously acquired imaging since the onset of the motor symptoms attributed to MSA.\n\nExclusion Criteria:\n\n* All Cohorts:\n\n  1. Clinical evidence of other neurodegenerative diseases, such as Alzheimer's disease\n  2. Any other medical or psychiatric condition or lab abnormality, which in the opinion of the investigator might preclude participation.\n  3. Received any of the following drugs: dopamine receptor blockers (neuroleptics), metoclopramide, lithium and reserpine, within 6 months of Baseline Visit.\n  4. Any other reason that in the opinion of the investigator, including abnormal labs, that could interfere with the safety with radiotracer injection, would render the participant unsuitable for the study enrollment.\n  5. Participation in an investigational drug trial targeting α-synuclein within the past 6 months prior to enrollment.\n  6. Currently being treated with and unable to safely hold antiplatelets (other than low dose aspirin up to 100mg\u002Fday) or anticoagulants prior to the procedure that might preclude safe attempt of Lumbar puncture, if applicable.\n  7. Condition that precludes the safe performance of routine lumbar puncture, if applicable, such as prohibitive lumbar spinal disease, bleeding diathesis, or clinically significant and uncorrected coagulopathy or thrombocytopenia.\n  8. Conditions or medications that preclude safe performance of imaging procedures (MRI or DaTscan), including but not limited to severe claustrophobia, MRI-incompatible metal implants, or known hypersensitivity to imaging agents.\n  9. Known hypersensitivity to DaTscan or iodine-containing compounds used as premedication for DaTscan. Participants with iodine sensitivity may still complete the imaging without iodine premedication at the investigator's discretion.\n  10. Use of medications known to interfere with DaTscan imaging (e.g., bupropion, amphetamines, methylphenidate, modafinil, alpha-methyldopa), unless the participant is willing and medically able to hold the medication for at least 5 half-lives or specified duration per investigators judgement prior to imaging.","50 Years","80 Years",{"count":454,"type":23},13,[159],"This is a single-center, open-label clinical study designed to evaluate the imaging characteristics and safety of \\[¹⁸F\\]MODAG-009 in participants with Parkinson's disease (PD), Multiple system atrophy (MSA), and Healthy controls (HC). Approximately 13 participants will be enrolled in this study. Each participant will receive a single intravenous injection of \\[¹⁸F\\]MODAG-009, followed by PET imaging using the investigational United Imaging NeuroEXPLORER (NX) camera.",[458,29,459],"Multiple System Atrophy (MSA)","Parkinson Disease",[461,462,463,464,465],"MODAG","MODAG GmbH","MODAG-009","PET Tracer","Synuclein","2026-06-06",{"date":468,"type":34},"2026-06-10",{"date":470,"type":34},"2026-05-13",{"date":472,"type":23},"2027-05",{"name":462,"class":41},{"id":475,"slug":476,"hasResults":12,"nctId":477,"briefTitle":478,"officialTitle":479,"acronym":480,"eligibilityCriteria":481,"healthyVolunteers":17,"sex":18,"minAge":482,"maxAge":451,"enrollmentInfo":483,"targetDuration":4,"studyType":24,"phases":484,"briefSummary":485,"conditions":486,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":487,"lastUpdatePostDateStruct":488,"startDateStruct":490,"completionDateStruct":492,"leadSponsor":493,"locationsCount":42},"100640661","modulation-of-appetite-signaling-through-enterohormone-stimulation-by-dnf-10-100640661","NCT07621393","Modulation of Appetite Signaling Through Enterohormone Stimulation by DNF-10","Modulation of Appetite Signaling Through Enterohormone Stimulation by DNF-10: Pilot Proof-of-concept, Crossover, Exploratory, Randomized, Double-blind, Placebo-controlled Study","DNF10-APET","Inclusion Criteria:\n\n* Healthy men and women aged 20 to 50 years.\n* Body Mass Index (BMI) of 18.5-24.9 kg\u002Fm² or 25.0-29.9 kg\u002Fm².\n* Stable use of permitted medications and\u002For dietary supplements during the study.\n* Individuals willing to maintain their usual dietary and physical activity habits throughout the study.\n* Subjects capable of understanding and complying with the study procedures.\n* Subjects who have signed the informed consent form.\n* Female participants must meet one of the following conditions:\n\n  1. Women with no potential for pregnancy, defined as women who have undergone surgical sterilization or who are postmenopausal.\n  2. Women of childbearing potential who use a highly effective contraceptive method (hormonal contraception, intrauterine device, condoms, male partner sterilization \\[vasectomy\\], or complete sexual abstinence) while participating in the study.\n\nExclusion Criteria:\n\n* Individuals with known eating behavior disorders (verified using the Spanish version of the Adult Eating Behavior Questionnaire, AEBQ).\n* Subjects with a body weight gain or loss ≥10% within the previous 3 months.\n* Treatment with medications or dietary supplements for weight loss, satiety, or glucose control.\n* Individuals consuming protein powders or dietary supplements related to the objectives of the study.\n* Participants receiving active treatment with GLP-1 receptor agonists or similar agents.\n* Participants taking medications or dietary supplements that, in the investigator's opinion, may interfere with the study objectives (e.g., affecting appetite), pose a safety risk, or confound the interpretation of the study results.\n* Depression or anxiety disorders that affect appetite.\n* High coffee consumption (more than 4 cups per day).\n* Smokers (more than 5 cigarettes per week), smoking during study assessment days, and\u002For drug abuse.\n* History of bariatric surgery within the last 3 years.\n* Low iron levels requiring treatment.\n* Individuals with renal or endocrine diseases (including diabetes).\n* Untreated or unstable hyperthyroidism, suicidal ideation, bipolar disorder, or evidence of any untreated or unstable neurological disorder.\n* Conditions or diseases that, in the investigator's judgment, may be worsened by participation in the study or may jeopardize the conduct of the study.\n* Presence of infectious diseases at the time of study inclusion (participants may be included 1 month after resolution of the illness).\n* Severely immunocompromised participants (transplant recipients, individuals treated with anti-rejection medications or steroids within the previous 30 days, or those who have received chemotherapy or radiotherapy within the last year).\n* Presence of active malignancy or any concomitant end-stage organ disease within the last 12 months that, in the investigator's judgment, contraindicates participation in the study.\n* Hypersensitivity, allergy, or intolerance to any of the components of the study product or standardized study menus (e.g., cow's milk protein allergy \\[CMPA\\], celiac disease, or non-celiac gluten intolerance).\n* Current participation or participation in another clinical trial within the previous three months.\n* Pregnant or breastfeeding women, women seeking pregnancy, or women of childbearing potential who are unwilling to use an effective contraceptive method.","20 Years",{"count":334,"type":23},[53],"This is a pilot, proof-of-concept, exploratory, randomized, double-blind, placebo-controlled crossover study. The study will be conducted in 50 healthy volunteers with a body mass index (BMI) between 18.5 and 29.9 kg\u002Fm². The objective is to comprehensively evaluate the potential of DNF-10 to modulate appetite through the regulation of enteroendocrine hormones and to determine its relevance in human physiology.",[29],"2026-06-02",{"date":489,"type":34},"2026-06-04",{"date":491,"type":34},"2026-05-12",{"date":206,"type":23},{"name":494,"class":41},"Fytexia",{"id":496,"slug":497,"hasResults":12,"nctId":498,"briefTitle":499,"officialTitle":499,"acronym":4,"eligibilityCriteria":500,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":501,"enrollmentInfo":502,"targetDuration":4,"studyType":24,"phases":504,"briefSummary":505,"conditions":506,"keywords":507,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":487,"lastUpdatePostDateStruct":513,"startDateStruct":514,"completionDateStruct":516,"leadSponsor":517,"locationsCount":42},"100640482","early-phase-1-evaluation-of-the-pharmacokinetics-biodistribution-and-radiation-dosimetry-of-18fmodag-009-positron-emission-tomography-pet-radiotracers-in-adult-healthy-volunteers-100640482","NCT07617688","Evaluation of the Pharmacokinetics, Biodistribution and Radiation Dosimetry of [18F]MODAG-009 Positron Emission Tomography (PET) Radiotracers in Adult Healthy Volunteers","Inclusion Criteria:\n\n* Male or Female,\n* aged 18 to 60 years old\n* in good health as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests at screening.\n* Ability to comply with the study procedures.\n* Able to understand and sign written informed consent from the participant.\n* Male and Females must meet additional criteria specified below, as applicable\n* a. Females must be of non-childbearing potential or using a highly effective method of birth control 14 days prior to until at least 24 hours after injection of \\[18F\\]MODAG-009. (i. Non-childbearing potential is defined as a female that must be either postmenopausal (no menses for at least 12 months prior to PET scan) or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy). ii. Highly effective method of birth control is defined as practicing at least one of the following: A birth control method that results in a less than 1% per year failure rate when used consistently and correctly, such as oral contraceptives for at least 3 months prior to injection, an intrauterine device (IUD) for at least 2 months prior to injection, or barrier methods, e.g., diaphragm or combination condom and spermicide. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) is not acceptable.)\n* b. Females of childbearing potential must not be pregnant, breastfeeding or lactating, or planning pregnancy during the duration of the study.\n* c. Males with female partners of childbearing potential must use adequate contraceptive methods and refrain from sperm donation for 90 days after injection of \\[18F\\]MODAG-009\n\nExclusion Criteria:\n\n* Use of any prescription drugs, herbal supplements, within four (4) weeks prior to initial dosing, and\u002For over-the-counter (OTC) medication, dietary supplements (vitamins included) within two (2) weeks prior to initial dosing. If needed (i.e. an incidental and limited need), acetaminophen is acceptable, but must be documented as a concomitant medication \u002F significant non-drug therapy. Participation in any clinical interventional studies within four (4) weeks prior to initial dosing or 5 half-lives of the investigational agent if known and longer than four (4) weeks.\n* Participants with a history of exposure to any radiation \\>50 mSv\u002Fyear (e.g., occupational or radiation therapy) over the past year. Donation or loss of 400 ml or more of blood within eight (8) weeks prior to initial dosing, or longer if required by local regulation.\n* Have a history or presence of any significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, or neurological disorders which, in the opinion of the investigator, are capable of altering the absorption, metabolism, or elimination of drugs or posing a health risk to participate in the study.\n* Have clinically significant findings on laboratory evaluations.\n* Have clinically significant findings on ECG evaluation.\n* History of immunodeficiency diseases, including a positive HIV test result.\n* A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C antibody test result.\n* History of drug or alcohol abuse within the 12 months prior to screening, or evidence of such abuse as indicated by the laboratory assays conducted during the screening.\n* History of tobacco product use within 3 months prior to screening, to be verified by urine cotinine screening.\n* Positive pregnancy test result, if female.\n* Women who are lactating and breastfeeding.","60 Years",{"count":503,"type":23},6,[159],"This is an open-label, single-center, phase 1 study to further characterize \\[18F\\]MODAG-009 in Healthy Volunteers (HV). Approximately 6 participants will be enrolled in this study. Each participant will receive a single dose of \\[18F\\]MODAG-009 radiotracer and undergo whole body PET imaging covering up to 10 bed positions to capture the whole body from skull vertex to mid-thigh.",[29],[461,462,465,508,509,510,511,512,463],"MSA","Multiple System Atrophy","Parkinson","Parkinson´s disease","PET tracer",{"date":489,"type":34},{"date":515,"type":34},"2026-05-27",{"date":472,"type":23},{"name":462,"class":41},{"id":519,"slug":520,"hasResults":12,"nctId":521,"briefTitle":522,"officialTitle":523,"acronym":4,"eligibilityCriteria":524,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":525,"enrollmentInfo":526,"targetDuration":4,"studyType":24,"phases":528,"briefSummary":529,"conditions":530,"keywords":532,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":534,"lastUpdatePostDateStruct":535,"startDateStruct":536,"completionDateStruct":538,"leadSponsor":540,"locationsCount":4},"100640012","phase-1-a-phase-i-single-and-multiple-dose-study-to-evaluate-the-safety-pharmacokinetics-and-pharmacodynamics-of-hs-10522-in-healthy-chinese-participants-and-chinese-participants-with-mild-hypertension-100640012","NCT07609875","A Phase I Single and Multiple Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of HS-10522 in Healthy Chinese Participants and Chinese Participants With Mild Hypertension","A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Oral Doses of HS-10522 Tablets in Healthy Chinese Participants and Chinese Participants With Mild Hypertension","Inclusion Criteria:\n\n\\-\n\nFor all participants:\n\n1. Able to understand the procedures and methods of the study, willing to strictly adhere to the clinical trial protocol to complete the study, and voluntarily sign the Informed Consent Form (ICF).\n2. Male or female participants aged 18 to 55 years (inclusive) at the time of signing ICF.\n3. At screening, body weight ≥ 50 kg for males and ≥ 45 kg for females, with a body mass index (BMI) between 19.0 and 28.0 kg\u002Fm² (inclusive).\n\nExclusion Criteria:\n\n1. Abnormal vital signs, physical examination findings, or laboratory test results at screening that are deemed clinically significant by the investigator.\n2. Presence of orthostatic hypotension or orthostatic tachycardia at screening.\n3. Clinically significant abnormal findings on the 12-lead ECG at screening, as judged by the investigator.\n4. Use of any medication within 2 weeks or 5 half-lives (whichever is longer) prior to screening, or anticipation of needing such medication during the trial.\n5. Known secondary causes of hypertension, or diseases that may affect adrenal function (e.g., renal artery stenosis, poorly controlled or untreated hyperthyroidism, poorly controlled or untreated hypothyroidism, hyperparathyroidism, pheochromocytoma, Cushing's syndrome).\n6. Participation in any other clinical trial of a drug or medical device within 12 weeks prior to screening, with receipt of at least one dose (including placebo), or currently within 5 half-lives of the last dose of the investigational product (whichever is longer).\n7. Participants who, in the opinion of the investigator, are likely to be non-compliant or are unsuitable for participation in this trial for any other reason.","55 Years",{"count":527,"type":23},88,[26],"The purpose of this study is to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of ascending single and multiple oral doses of HS-10522 in healthy Chinese participants and Chinese participants with mild hypertension.",[29,531],"Hypertension",[533],"hypertension","2026-05-19",{"date":515,"type":34},{"date":537,"type":23},"2026-06-01",{"date":539,"type":23},"2027-02-03",{"name":541,"class":41},"Jiangsu Hansoh Pharmaceutical Co., Ltd.",{"id":543,"slug":544,"hasResults":12,"nctId":545,"briefTitle":546,"officialTitle":547,"acronym":4,"eligibilityCriteria":548,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":525,"enrollmentInfo":549,"targetDuration":4,"studyType":24,"phases":551,"briefSummary":552,"conditions":553,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":554,"lastUpdatePostDateStruct":555,"startDateStruct":557,"completionDateStruct":558,"leadSponsor":560,"locationsCount":42},"100637255","phase-1-bioequivalence-study-of-ferric-carboxymaltose-injection-in-healthy-chinese-participants-under-fasting-conditions-100637255","NCT07606105","Bioequivalence Study of Ferric Carboxymaltose Injection in Healthy Chinese Participants Under Fasting Conditions","A Randomized, Open-label, Two-treatment, Two-period, Two-cross-over Bioequivalence Study of Ferric Carboxymaltose Injection in Healthy Chinese Participants Under Fasting Conditions","Inclusion Criteria:\n\n1. Participants must fully understand the purpose, nature, procedures, and potential adverse reactions of the study. They must voluntarily agree to participate in the trial, comply with all study requirements, and provide written informed consent before the initiation of any study procedures.\n2. Healthy male or female participants aged 18 to 55 years (inclusive).\n3. Participants must have a body weight of ≥ 50.0 kg; Body Mass Index(BMI) must range from 19.0 to 26.0 kg\u002Fm² (inclusive).\n4. Participants have been using effective contraception for 14 days prior to screening. Participants must agree to use highly effective contraceptive measures from screening until 3 months after the last administration. They must have no plans for pregnancy, sperm donation, or egg donation during this period.\n\nExclusion Criteria:\n\n1. Participants with allergic conditions, such as a known history of hypersensitivity to two or more medications; known allergies to iron, maltose, or its analogues\u002F metabolites; or a history\u002Fpresence of severe asthma, eczema, or other atopic allergic disorders.\n2. History\u002Fpresence of iron storage diseases (e.g., hemochromatosis), iron utilization disorders (e.g., iron-refractory iron deficiency anemia), hemoglobinopathies (e.g., thalassemia), hemolytic anemia, symptomatic anemia requiring red blood cell infusion, or undergoing hemodialysis.\n3. History of iron deficiency or anemia within 6 months prior to screening.\n4. History of clinically significant chronic or severe conditions affecting the respiratory, cardiovascular, gastrointestinal, renal, hematological, lymphatic, endocrine, immune, psychiatric, or nervous systems; past or current diagnosis of porphyria cutanea tarda; or other conditions deemed by the investigator to be unsuitable for participation.\n5. Acute conditions (e.g., acute infection, acute gastrointestinal disorders such as nausea, vomiting, diarrhea, or constipation, etc.) within 2 weeks prior to the first dose.\n6. Participants with clinically significant abnormalities in vital signs, physical examination, laboratory tests (e.g., hematology, urinalysis, blood chemistry, coagulation function tests, iron metabolism assessments), infectious disease testing, or 12-lead Electrocardiogram (ECG), as determined by the investigator (special requirement: calcium and phosphorus values in blood chemistry tests are in the abnormal range). Hepatic enzyme levels exceeding 1.5 times the upper limit of normal (ULN) during screening. Serious arrhythmias shown in ECG at screening, such as recurrent or symptomatic ventricular tachycardia, atrial fibrillation accompanied by rapid ventricular response, or supraventricular tachycardia.\n7. History of hypersensitivity or intolerance to intravenous iron administration.\n8. Receiving parenteral iron treatment within 6 months prior to screening, erythropoiesis-stimulating agent (ESA) therapy and\u002For blood transfusion within 4 weeks prior to screening.\n9. Use of any medication that may affect iron absorption iron absorption within 28 days prior to dosing, such as antacids (e.g., omeprazole), tetracycline antibiotics, calcium supplements, or lipid-lowering agents (e.g., cholestyramine).\n10. Use of any medications (prescription, over-the-counter, herbal remedies, or dietary supplements) and healthcare products within 2 weeks prior to screening.\n11. History of smoking an average of more than 5 cigarettes per day within 3 months prior to screening or unwillingness to abstain from smoking from 48 hours prior to dosing until the completion of blood sampling in each treatment period.\n12. Participants who have undergone surgeries within 6 months prior to screening that might affect drug absorption, distribution, metabolism and excretion, or planning to undergo surgeries during the study.\n13. Participants who have enrolled in other clinical trials and received investigational products or devices within 3 months prior to screening.\n14. Blood donation or significant blood loss due to other reasons within 3 months prior to screening (\\> 400 mL, excluding menstrual blood loss in female participants), or donated platelets in an amount equal to or exceeding 2 therapeutic doses (1 therapeutic dose = 12 units of platelets) within 1 month prior to screening, or plan to donate blood during the study.\n15. Participants with drug abuse history (including the use of various anesthetic and psychotropic drugs for non-medical purposes) within 1 year prior to screening or have a positive drug abuse screening result.\n16. Participants with history of alcohol abuse within 1 year prior to screening, defined as average daily alcohol consume over 2 units (1 unit = 360 mL beer, 45 mL spirits with 40% alcohol, or 150 mL wine), or are unwilling to abstain from alcohol or alcohol-containing products from 48 hours prior to dosing until the completion of blood sampling in each treatment period, or have positive breath alcohol test result.\n17. Participants who have special diet: xanthine-rich foods (e.g., coffee, chocolate, tea or cocoa beverages), iron-rich foods including animal organs, animal blood, spinach, as well as calcium\u002Fphosphorus-rich seafood, shellfish, crab, and nuts such as peanuts and sunflower seeds, dragon fruit, mango, grapefruit or grapefruit-containing products, or taking strenuous exercise, or other factors affecting drug absorption, distribution, metabolism, and excretion, within 48 hours before receiving the first dose of investigational product.\n18. Participants who received a live vaccine within 14 days prior to screening, or plan to receive vaccination during the study.\n19. Inability to tolerate venipuncture or history of fear of needles or hemophobia.\n20. Participants with special dietary requirements, and participants who cannot accept the study standardized diet.\n21. Any other condition deemed by the investigator to be unsuitable for enrollment.\n\n    In addition to the aforementioned requirements, females who meet the following conditions should also be excluded:\n22. Use of oral contraceptives within 30 days prior to screening.\n23. Use of long-acting estrogen or progestin injections (progestin-based intrauterine devices), or implants within 6 months prior to screening.\n24. Pregnancy, breastfeeding, or positive pregnancy test at screening.",{"count":550,"type":23},70,[26],"The goal of this clinical trial is to compare the pharmacokinetic profile of the developed drug product and reference product in healthy participants under fasting condition. The main questions it aims to answer are:\n\n* \\[Question 1\\] Is there significant difference in the pharmacokinetic profile between the ferric carboxymaltose injection 750 mg iron\u002F15 mL provided by Sichuan Huiyu Pharmaceutical Co., Ltd. and the ferric carboxymaltose injection licensed by American Regent, Inc. (trade name: Injectafer®, strength:750 mg iron\u002F15 mL )?\n* \\[Question 2\\] Is it safe for healthy participants to take ferric carboxymaltose injection (750 mg iron\u002F15 mL \\[calculated by iron\\]) provided by Sichuan Huiyu Pharmaceutical Co., Ltd. under fasting condition? Participants will be randomly divided into two groups by stratified blocked randomization, with equal number of healthy participants in each group, to receive test product or reference product according to the protocol below.\n* Dosing on D1: Group T (Test product) Group R (Reference product)\n* PK blood sample collection\n* Safety evaluation",[29],"2026-05-18",{"date":556,"type":34},"2026-05-26",{"date":534,"type":23},{"date":559,"type":23},"2027-01-26",{"name":561,"class":41},"Sichuan Huiyu Pharmaceutical Co., Ltd",{"id":563,"slug":564,"hasResults":12,"nctId":565,"briefTitle":566,"officialTitle":567,"acronym":568,"eligibilityCriteria":569,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":570,"enrollmentInfo":571,"targetDuration":4,"studyType":24,"phases":573,"briefSummary":574,"conditions":575,"keywords":577,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":586,"lastUpdatePostDateStruct":587,"startDateStruct":589,"completionDateStruct":591,"leadSponsor":592,"locationsCount":42},"100635062","effects-of-a-robot-based-sensorimotor-upper-limb-rehabilitation-paradigm-in-chronic-stroke-100635062","NCT07547800","Effects of a Robot-based Sensorimotor Upper Limb Rehabilitation Paradigm in Chronic Stroke","Effects of a Robot-based Sensorimotor Upper Limb Rehabilitation Paradigm in Chronic Stroke: a Randomized Controlled Trial","RCT ROBUST","Inclusion Criteria stroke participants:\n\n1. Written informed consent must be obtained prior to any screening procedures;\n2. A first-ever unilateral, supra-tentorial stroke, as defined by WHO (rapidly developing clinical signs of focal (or global) disturbance of cerebral function, with symptoms lasting 24 hours or longer or leading to death, with no apparent cause other than vascular origin);\n3. ≥18 and ≤85 years old;\n4. Being a Dutch speaker;\n5. Being in the chronic phase after stroke, i.e. \\> 6 months post stroke;\n6. Motor impairment in the upper limb, defined as Fugl-Meyer score \\>22 out of 66 to demonstrate moderate to full upper limb motor function (patients scoring \\\u003C23 out of 66 will not be able to comply with the Kinarm protocol);\n7. Residual sensory upper limb impairment, defined as Tactile Discrimination Test (Area Under Curve) \\\u003C73.10%;\n8. Impaired functionality, defined as sensorimotor Action Research Arm Test score \\\u003C52 out of 57;\n9. Manageable spasticity for Kinarm tasks.\n\nInclusion Criteria healthy participants:\n\n1. Written informed consent must be obtained prior to any screening procedures;\n2. ≥18 and ≤85 years old;\n3. Being a Dutch or English speaker;\n4. No history of stroke or transient ischemic attack;\n5. No recent brain\u002Fhead injury;\n6. No major upper limb sensory or motor impairments.\n\nExclusion Criteria:\n\n1. Having musculoskeletal and\u002For other neurological disorders impacting care or prognosis;\n2. Having severe communication or cognitive deficits that interfere with the protocol;\n3. Having severe spasticity (cannot handle Kinarm robot);\n4. Any disorder, which in the investigator's opinion might jeopardise participant's safety or compliance with the CIP;\n5. Contraindications for robot-based therapy (e.g., uncontrolled epilepsy);\n6. Participation in another clinical investigation;\n7. Having any contraindications for fNIRS\\*：\n\n   * Uncontrolled head movements (e.g. tremor)\n   * Scalp lesion at optode sites (wound\u002Fincision\u002Finfection\u002Fhematoma)\n   * Decompressive craniectomy or large skull defect over target regions\n   * Persistent hair-optode coupling failure despite best practices, or non-removable obstructions preventing adequate coupling\n8. Having any contraindications for MRI\\*\\*:\n\n   * Pacemaker\n   * Implantable Cardioverter Defibrillator (ICD)\n   * Cochlear implant\n   * Internal Insulin-pump\n   * Deep brain stimulation\n   * Any other metal device in the body\n   * Claustrophobia\n   * Having a history of a neuropsychiatric or neurologic disorder before the diagnosis of stroke (e.g., depression, traumatic brain injury)\n   * Use of psychoactive medication before the diagnosis of stroke (e.g., anti-depressive medication)\n   * Misuse (or history of misuse) of drugs\u002Falcohol\n9. Currently undergoing a structured arm and\u002For hand training (e.g. engaging in playing a musical instrument)\\*\\*.\n\n   * Stroke patients and healthy participants showing these exclusion criteria will be included in the RCT protocol, but will not be measured with fNIRS.\n\n     * Stroke patients showing these exclusion criteria will be included in the RCT protocol, but will not be measured with MRI. Healthy adults showing these exclusion criteria will not be included in the study.","85 Years",{"count":572,"type":23},109,[53],"Sensorimotor function of the upper limb is commonly impaired after stroke, even in the chronic phase (\\>6 months post-stroke). Nevertheless, good sensorimotor function is needed for daily life functioning. Sensorimotor function can be divided into three components: exteroception, proprioception and sensory processing. It is important that those three components will each be addressed in the upper limb rehabilitation. Unfortunately, there is still no optimal therapy to address sensory processing. Therefore, the investigators developed an intensive sensorimotor robot-based rehabilitation paradigm (called ROBUST) with focus on sensory processing. As a first step, the investigators did a pilot study (S69003) including 10 persons with chronic stroke to investigate the potential effectiveness and feasibility of this novel rehabilitation. The median change score of motor, sensory and sensorimotor assessments was exceeding the minimal clinical important difference (MCID), and the total amount of therapy was feasible as well. The investigated protocols to measure potential changes in brain function (activity and connectivity) and structure accompanying the novel therapy appeared feasible as well. Based on this first pilot study, the investigators finalized the protocol for this RCT to investigate the effectiveness of the ROBUST intervention.",[576,29],"Stroke",[576,578,579,580,581,582,583,584,585],"Upper limb","Sensorimotor","Sensory processing","Robot-based therapy","MRI","fNIRS","Clinical outcomes","Kinematic outcomes","2026-05-06",{"date":588,"type":34},"2026-05-11",{"date":590,"type":23},"2026-04-17",{"date":295,"type":23},{"name":593,"class":76},"KU Leuven",{"id":595,"slug":596,"hasResults":12,"nctId":597,"briefTitle":598,"officialTitle":599,"acronym":4,"eligibilityCriteria":600,"healthyVolunteers":12,"sex":601,"minAge":19,"maxAge":183,"enrollmentInfo":602,"targetDuration":4,"studyType":24,"phases":604,"briefSummary":605,"conditions":606,"keywords":607,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":612,"lastUpdatePostDateStruct":613,"startDateStruct":615,"completionDateStruct":616,"leadSponsor":618,"locationsCount":42},"100636572","digital-game-and-simulation-in-midwifery-education-100636572","NCT07567430","Digital Game and Simulation in Midwifery Education","The Effect Of Dıgıtal Game-Based Learnıng On Learnıng Motıvatıon And Attıtude In Preeclampsıa-Eclampsıa Educatıon In Mıdwıfery Students: Comparıson Wıth Sımulatıon And Tradıtıonal Educatıon","Inclusion Criteria:\n\n* Being an undergraduate midwifery student (4th year).\n* Giving written consent to the study.\n\nExclusion Criteria:\n\n* Having previously received advanced training or clinical assignment in preeclampsia\u002Feclampsia management.\n* Regularly using a similar digital game developed on the subject.\n* Health or cognitive limitations that prevent continuation of the research process (according to the student's statement).","FEMALE",{"count":603,"type":23},120,[53],"Preeclampsia and eclampsia are among the leading causes of maternal death and morbidity, and are obstetric emergencies that lead to serious complications during pregnancy. Preeclampsia affects 2-8% of pregnancies worldwide; approximately 46,000 maternal deaths and approximately 500,000 fetal or neonatal deaths occur annually due to preeclampsia. This situation highlights the importance of well-equipped midwifery care, especially in terms of early diagnosis, accurate assessment, emergency intervention, and effective management.\n\nTraditional teaching methods alone are insufficient for midwifery students to develop clinical decision-making skills in life-threatening situations such as preeclampsia and eclampsia, and to translate theoretical knowledge into practice. Therefore, new teaching approaches that support active learning, interaction, and decision-making processes in education are needed.\n\nIn recent years, digital game-based learning has emerged as an innovative tool in health education with its potential to attract learners' attention, improve problem-solving skills, and increase their motivation. Especially for midwifery students, digital games facilitate experiential learning by providing a safe simulation environment in preparation for information overload and stressful clinical environments.\n\nHowever, the use of digital games in teaching complex clinical processes such as preeclampsia and eclampsia management has been researched to a limited extent. Scientifically examining the effects of such innovative methods on students' learning motivation, attitude, and active participation in the learning process in midwifery education will fill an important gap in the literature. In this context, evaluating digital game-based learning in preeclampsia-eclampsia management education by comparing it with simulation training and traditional teaching will make a significant contribution to both the midwifery education literature and the knowledge base regarding the use of technology in health education.",[29],[608,609,610,611],"digital game based learning","preeclampsia","eclampsia","midwifery education","2026-05-03",{"date":614,"type":34},"2026-05-05",{"date":537,"type":23},{"date":617,"type":23},"2027-01-30",{"name":619,"class":76},"Medipol University",{"id":621,"slug":622,"hasResults":12,"nctId":623,"briefTitle":624,"officialTitle":625,"acronym":626,"eligibilityCriteria":627,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":501,"enrollmentInfo":628,"targetDuration":4,"studyType":24,"phases":629,"briefSummary":630,"conditions":631,"keywords":633,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":643,"lastUpdatePostDateStruct":644,"startDateStruct":646,"completionDateStruct":647,"leadSponsor":649,"locationsCount":42},"100636095","effects-of-repetitive-transcranial-magnetic-stimulation-on-two-cerebellar-targets-100636095","NCT07561229","Effects of Repetitive Transcranial Magnetic Stimulation on Two Cerebellar Targets","Effects of Repetitive Transcranial Magnetic Stimulation (rTMS) on Two Cerebellar Targets (Lobule VIII vs. CRUS I\u002FII)","StimCervelet","Inclusion Criteria:\n\n* Subject, male or female, aged between 18 and 60 years inclusive\n* Subject affiliated with or a beneficiary of a social security health insurance scheme\n* Subject has dated and signed the informed consent form prior to the start of any trial-related procedures\n* For women of childbearing potential, a negative urinary pregnancy test and the use of effective contraception throughout the duration of the study\n\nExclusion Criteria:\n\n* Subject with substance use disorders (as defined by the DSM-5)\n* Subject having taken benzodiazepines and related compounds (within the period preceding inclusion, for a duration equivalent to 5 half-lives of the product), cannabis (within the 2 months preceding inclusion), or hallucinogenic substances (within the period preceding inclusion, for a duration equivalent to 5 half-lives of the product)\n* Subject suffering from a neurological pathology or sequelae\n* Subject with Attention-Deficit\u002FHyperactivity Disorder (ADHD)\n* Subject with Borderline Personality Disorder\n* Subject presenting with disabling sensory impairments, specifically a visual acuity (corrected, if applicable) \\\u003C 0.8 (due to the use of visual materials; Freiburg Vision Test, Bach 1996; verified during an examination at the screening visit)\n* Subject deprived of liberty or under legal protection\n* Subject under guardianship or trusteeship\n* Pregnant or breastfeeding woman (verified by a urinary test at the screening visit)\n* Subject within an exclusion period defined by another clinical study or participating in a study likely to impact the results of the research\n* Subject presenting a contraindication for fMRI or rTMS: presence of non-removable ferromagnetic bodies, prostheses, pacemakers, implanted medication pumps, vascular clips or stents, heart valves or ventricular shunts, certain intracerebral clips, cochlear implants, history of seizures (epilepsy), or skin breach\u002Fpathology at the point of contact with the electrodes\n* Subject with a history of major neurological or psychiatric disease with current psychotropic medication (i.e., antipsychotics, benzodiazepines and related compounds, or hypnotics)",{"count":107,"type":23},[53],"The purpose of this study is to understand how different areas of the cerebellum (a part of the brain) control different functions and how they can be influenced by non-invasive brain stimulation.\n\nWhile researchers know that repetitive Transcranial Magnetic Stimulation (rTMS) can have positive effects on conditions like stroke and schizophrenia, they do not yet fully understand which specific stimulation settings work best or which exact parts of the cerebellum should be targeted for different symptoms.\n\nThis study compares the effects of stimulation on two specific regions:\n\n* Lobule VIII: Linked to movement and motor learning.\n* CRUS I\u002FII: Linked to attention, thinking (cognition), and predicting the timing of events.By comparing these areas, researchers hope to gain the information needed to develop better treatments for neurological and psychiatric disorders.\n\nThis is a randomized, double-blind study involving 40 healthy volunteers. Participants will be split into two groups:\n\n* Group 1: Receives \"exciting\" (activity-increasing) stimulation.\n* Group 2: Receives \"inhibiting\" (activity-decreasing) stimulation.\n\nEach participant will attend three different test sessions in a random order:\n\n* rTMS targeting Lobule VIII\n* rTMS targeting CRUS I\u002FII\n* Placebo (Sham) stimulation that looks and feels like the real thing but does not affect the brain.\n\nDuring each session, researchers will use brain imaging (fMRI) and computerized tasks to measure changes in brain connectivity and performance in motor and cognitive activities.\n\nThere is no direct medical benefit to the participants. However, the results will help scientists create better therapies for patients with brain-related health issues The risks are considered minimal. Common side effects of rTMS include temporary mild headaches or a clicking sound during stimulation. MRI scans can sometimes cause mild discomfort or a feeling of closed-in spaces (claustrophobia). Researchers have put safety measures in place, such as hearing protection and constant medical supervision during scans, to minimize these risks.",[632,29],"Healthy",[634,635,636,637,638,639,640,641,642],"Repetitive Transcranial Magnetic Stimulation (rTMS)","Cerebellum","Lobule VIII","Crus I\u002FII","Resting-state functional Magnetic Resonance Imaging (rs-fMRI)","Neuromodulation","Neuroplasticity","Excitatory vs. Inhibitory Stimulation","Neurotypical","2026-04-27",{"date":645,"type":34},"2026-05-01",{"date":249,"type":23},{"date":648,"type":23},"2030-01-02",{"name":650,"class":76},"University Hospital, Strasbourg, France",{"id":652,"slug":653,"hasResults":12,"nctId":654,"briefTitle":655,"officialTitle":656,"acronym":657,"eligibilityCriteria":658,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":659,"targetDuration":4,"studyType":24,"phases":660,"briefSummary":661,"conditions":662,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":664,"lastUpdatePostDateStruct":665,"startDateStruct":667,"completionDateStruct":669,"leadSponsor":670,"locationsCount":4},"100636324","foam-roller-compared-to-massage-on-reducing-calf-muscle-tone-in-healthy-subjects-100636324","NCT07564206","Foam Roller Compared to Massage on Reducing Calf Muscle Tone in Healthy Subjects","Effect of Foam Roller Compared to Massage on Reducing Calf Muscle Tone in Healthy Subject","FRTONE","Inclusion Criteria:\n\n1. Age: Participants aged between 18 and 45 years.\n2. Health Status: Healthy individuals with no prior musculoskeletal conditions in the lower limbs.\n3. Pain-Free: Participants should not have had pain in the gastrocnemius or Achilles tendon in the last 3 months.\n4. Willingness: Participants must provide informed consent and be available for the intervention and necessary evaluations.\n\nExclusion Criteria:\n\n1. Musculoskeletal Conditions: Individuals with any pathologies in the calf muscles (gastrocnemius, soleus) or Achilles tendon.\n2. Vascular or Neurological Issues: Participants with vascular diseases or neurological disorders that may interfere with the interventions or muscle response.\n3. Skin Conditions: Exclusion of participants with skin alterations, infections, or open wounds in the area of intervention.\n4. Pregnancy: Women who are pregnant.\n5. Sensitivity Issues: Participants with altered sensitivity in the lower limbs or any condition that may affect the response to the techniques.\n6. Non-Compliance: Individuals who do not provide informed consent or are not available for the required evaluations.",{"count":157,"type":23},[53],"Objective: This study aims to compare the effects of two techniques-foam rolling (FR) and therapeutic massage-on reducing the muscle tone in the calf muscles (gastrocnemius and soleus) of healthy individuals.\n\nMethods: A randomized, controlled crossover design was used with 40 healthy participants (aged 18-45). Participants were randomly assigned to either a foam roller or a therapeutic massage group. The interventions were applied to the dominant leg, and muscle tone was measured pre- and post-intervention using a MyotonPro device. The primary outcome was muscle tone (Hz), and secondary outcomes included muscle stiffness (N\u002Fm) and elasticity (D \\[log\\]).\n\nResults: The study will assess the effectiveness of each intervention on muscle tone, stiffness, and elasticity. It aims to determine whether foam rolling is as effective or superior to traditional massage in reducing calf muscle tone.\n\nConclusion: This research will contribute to understanding the efficacy of foam rolling as a self-administered technique for muscle tone reduction and its potential application in clinical and athletic settings",[663,29],"Muscle Tone","2026-04-26",{"date":666,"type":34},"2026-05-04",{"date":668,"type":23},"2026-05-15",{"date":203,"type":23},{"name":671,"class":76},"Universidad Europea de Madrid"]